Serum galectin-3 levels in women with PCOS

Basit Öğe Kaydı
dc.authoridAbusoglu, Sedat/0000-0002-2984-0527|ATALAY, CEMAL RESAT/0000-0002-0148-0945|ozdemir, ozhan/0000-0002-0930-775X
dc.contributor.authorYilmaz, H.
dc.contributor.authorCelik, H. T.
dc.contributor.authorOzdemir, O.
dc.contributor.authorKalkan, D.
dc.contributor.authorNamuslu, M.
dc.contributor.authorAbusoglu, S.
dc.contributor.authorAtalay, C. R.
dc.date.accessioned2025-10-24T18:08:53Z
dc.date.available2025-10-24T18:08:53Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAim Galectin-3 (Gal-3) plays a role in modulation of adiposity, glucose hemostasis and inflammation. The association between Gal-3 and the polycystic ovary syndrome (PCOS), is not investigated. We aimed to evaluate galectin-3 levels in serum and their relation with hyperandrogenism and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) and in control subjects. Materials and methods 56 women with PCOS were enrolled along with a control group of 41 healthy women, matched for age and body mass index. We measured hormonal and metabolic parameters, as well as the serum galectin-3 concentration of each participant. We estimated the IR according to the homeostasis model assessment-insulin resistance (HOMA-IR). Results Women with PCOS had higher levels of serum Gal-3 compared to healthy individuals 3,588.77 +/- 1,566.94 vs 2,491.33 +/- 812.04, P < 0.001). Serum Gal-3 levels were correlated with progesterone (r = 0.241, P = 0.025), hirsutism score (r = 0.296, P = 0.006), insulin (r = 0.479, P = 0.028), HOMA-IR (r = 0.514, P = 0.017), dehydroepiandrosterone sulfate (r = 0.246, P = 0.022), testosterone (r = 0.252, P = 0.019), and free testosterone (r = 0.306, P = 0.004). Conclusion Galectin-3 levels are higher in patients with PCOS, and there is a positive correlation between galectin-3 level and IR, androgen levels and hirsutismus scores. Gal-3 may be a new mediator of PCOS via IR, hyperandrogenism.
dc.identifier.doi10.1007/s40618-013-0032-y
dc.identifier.endpage187
dc.identifier.issn1720-8386
dc.identifier.issue2
dc.identifier.pmid24497217
dc.identifier.scopus2-s2.0-84900552114
dc.identifier.scopusqualityQ1
dc.identifier.startpage181
dc.identifier.urihttps://doi.org/10.1007/s40618-013-0032-y
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3360
dc.identifier.volume37
dc.identifier.wosWOS:000335151700010
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal Of Endocrinological Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectHyperandrogenemia; PCOS; Insulin resistance; Galectin-3
dc.titleSerum galectin-3 levels in women with PCOS
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu